Add 2 More Reports For 20% off

Report Overview

2024

Base Year

2018-2024

Historical Year

2025-2034

Forecast Year

Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Outlook

The chronic inflammatory demyelinating polyneuropathy treatment market attained a value of USD 4.13 billion in 2024. The market is expected to rise at a CAGR of 6.9% in the forecast period of 2025-2034 and is anticipated to be worth USD 7.52 billion by 2034.

Chronic Inflammatory Demyelinating Polyneuropathy: Disease Insights

Chronic inflammatory demyelinating polyneuropathy is a rare neuroinflammatory disorder. The destruction of nerve fibre myelin sheaths and inflammation of nerve roots takes place in this disorder. The reduction of myelin causes nerve signals blockage and thus, substantial loss in the nerve fibres.

The severity of the disease, duration of disease and symptoms vary from patient to patient. The common signs and symptoms of chronic inflammatory demyelinating polyneuropathy are impaired body movements, weakness of both muscles and paralysis in extreme cases. The disfigurement in the motor and sensory functions affects both sides of the body.

chronic inflammatory demyelinating polyneuropathy treatment market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

There are different variants of chronic inflammatory demyelinating polyneuropathy such as multifocal variants, pure sensory variants, distal variants, and pure motor variants. The exact cause of CIDP is still not clear, but the studies suggest, it to be an autoimmune disorder.

The diagnosis of chronic inflammatory demyelinating polyneuropathy is a bit complicated, due to the very common symptoms. Electromyography is the primary test used to analyse the velocities of nerve conduction. Lumbar puncture and MRI imaging are the additional diagnostic tests of CIDP. These tests help in the detection of enlargement and indications of pain.

Several approved treatments are used for the management of chronic inflammatory demyelinating polyneuropathy.

According to the chronic inflammatory demyelinating polyneuropathy treatment market research report, the market can be categorised into the following segments:

Market Breakup by Therapeutic Method

  • Corticosteroids
  • Intravenous Immunoglobulin
  • Plasma exchange
  • Immunotherapy
  • Stem Cell Transplant
  • Physical therapy
  • Others

Market Breakup by Diagnosis

  • Electrodiagnostic Testing
  • Nerve Conduction
  • Electromyography
  • Spinal Fluid Analysis
  • Others

Market Breakup by Route of Administration

  • Intravenous
  • Oral
  • Others

Market Breakup by End User

  • Hospitals
  • Specialty Neurological Clinics
  • Research and Academic Laboratories

Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

chronic inflammatory demyelinating polyneuropath  treatment market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Scenario

The increasing incidence and prevalence of CIDP are driving the growth of the chronic inflammatory demyelinating polyneuropathy treatment market. According to National Organisation for Rare Disorders, every 5-7 individuals per 100,000 are diagnosed with CIDP. The rising cases of CIDP are propelling the demand for the treatment market.

The growing research and development activities will lead to the discovery of novel targeted therapies. At present, according to clinicaltrials.gov, more than thirty-eight clinical trials are under current evaluation.

The CIDP organisations and international support groups are creating awareness regarding the diagnosis and treatment of CIDP. Raising awareness and support initiatives have stimulated the growth of the market.

With technological advancements, there are innovations in diagnostic tools and interventions. This will assist in more specific and accurate detection. The advancements in diagnostic techniques are also aiding the growth of the market.

North America Accounts for the Largest Share

North America is anticipated to hold the maximum share in the CIDP market. Increased expenditure in the healthcare sector and greater research and developmental activities are driving the growth of the chronic inflammatory demyelinating polyneuropathy treatment market.

Therapeutic Landscape

There are multiple therapeutic strategies approved for the management of chronic inflammatory demyelinating treatment. The available treatments suppress the immune system and thus, there are high chances of infections and other related disorders.

Standard Therapies: Corticosteroids, Immunoglobins, Plasma Exchange and Immunosuppressants are Aiding the Growth of the Market

Glucocorticosteroids are the first-line medications for treating CIDP. These drugs are used in combination with other immunosuppressive drugs to provide more efficient treatment. Prednisone is one of the most common drugs belonging to this category.

Intravenous immunoglobin has also shown promising effects in the treatment of CIDP. This therapy increases immunity and assists in the treatment. Subcutaneous immunoglobin delivery is an alternative form of IVIG therapy.

Plasma Exchange is the chronic treatment for the management of chronic inflammatory demyelinating polyneuropathy. In this therapeutic procedure, immunoglobins and other components are extracted from the immunity system. The plasma and its constituents are also removed from the affected individual and then replaced with albumin. The blood cells are transfused back into the patient. 

Immunosuppressive agents are also used for treating chronic inflammatory demyelinating polyneuropathy. Some examples of such agents are mycophenolate, cyclosporine, and azathioprine. The discovery of novel immunosuppressants is anticipated to fuel the chronic inflammatory demyelinating polyneuropathy treatment market growth.

chronic inflammatory demyelinating polyneuropathy treatment market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Clinical Trial Landscape

With the increase in disease prevalence, there is a need for novel therapeutic interventions. These new treatments are anticipated to provide lucrative opportunities in the therapeutic sector.

Emerging Therapies: Monoclonal Antibodies, FcRN Inhibitors, and HYQVIA Therapy

The clinical trials for the incorporation of monoclonal antibodies in the standard treatments are under evaluation. Monoclonal antibodies are artificially made proteins resembling the immune system’s pathogenic defence mechanism.

Rituximab, a monoclonal antibody has recently been approved by the USFDA for the treatment of multiple sclerosis and rheumatoid arthritis.

The investigation for reducing circulating immunoglobins is also under process. These studies incorporate the activity of FcRN inhibitors that will assist in the management of chronic inflammatory demyelinating polyneuropathy.

Takeda, a key player is performing the final stage of clinical trials for a recombinant therapy HYQVIA. This therapy incorporates human hyaluronidase with a ten per cent infusion of human immunoglobins. The company aims to get approvals from the USFDA and EMA by the end of 2023. If approved, this can be used as maintenance therapy for alleviating the symptoms of chronic inflammatory demyelinating polyneuropathy.

Implementing advanced technologies in healthcare has already provided enormous benefits to human health. Researchers’ tremendous efforts have anticipated a rapid increase in the approvals for recombinant therapies. Several ongoing clinical trials are emerging as a driving factor for the market growth and development.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the chronic inflammatory demyelinating polyneuropathy treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

  • Grifols, S.A.
  • Octapharma AG
  • Baxter International Inc.
  • Pfizer Inc.
  • CSL Behring LLC
  • MedDay SA
  • Shire plc
  • Takeda Pharmaceutical Company Limited
  • Teijin Limited
  • Momenta Pharmaceuticals, Inc.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2018-2024
Forecast Period 2025-2034
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Therapeutic Method
  • Diagnosis
  • Route of Administration
  • End User
  • Region
Breakup by Therapeutic Method
  • Corticosteroids
  • Intravenous Immunoglobulin
  • Plasma Exchange
  • Immunotherapy
  • Stem Cell Transplant
  • Physical Therapy
  • Others
Breakup by Diagnosis
  • Electrodiagnostic Testing
  • Nerve Conduction
  • Electromyography
  • Spinal Fluid Analysis
  • Others
Breakup by Route of Administration
  • Intravenous
  • Oral
  • Others
Breakup by End User
  • Hospitals
  • Specialty Neurological Clinics
  • Research and Academic Laboratories
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
  • Industry Events, Initiatives & Trends
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Grifols, S.A.
  • Octapharma AG
  • Baxter International Inc.
  • Pfizer Inc.
  • CSL Behring LLC
  • MedDay SA
  • Shire plc
  • Takeda Pharmaceutical Company Limited
  • Teijin Limited
  • Momenta Pharmaceuticals, Inc.

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The market attained a value of USD 4.13 billion in 2024.

The market is expected to rise at a CAGR of 6.9% in the forecast period of 2025-2034 and is anticipated to reach USD 7.52 billion by 2034.

Chronic inflammatory demyelinating polyneuropathy is a rare neuroinflammatory disorder. The destruction of nerve fibre myelin sheaths and inflammation of nerve roots takes place in this disorder.

Based on the therapeutic method, the market is segmented into corticosteroids, intravenous immunoglobulins, plasma exchange, immunotherapy, stem cell transplant, and physical therapy, among others.

The regions are North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Based on the diagnosis, the market is bifurcated into electrodiagnostic testing, nerve conduction, electromyography, spinal fluid analysis and others.

The end-users are hospitals, speciality neurological clinics, and research and academic laboratories.

The increasing prevalence of chronic inflammatory demyelinating polyneuropathy, rising awareness and growing research and development activities are driving the market growth.

North America is anticipated to hold a significant share in the market during the forecast period.

The key companies involved in the market are Grifols, SA, Octapharma AG, Baxter International Inc., Pfizer, Inc., CSL Behring, GE Neuro, MedDay Pharmaceuticals, Shire, Takeda Pharmaceuticals, Teijin Pharma, Momenta Pharmaceuticals, among others.

Datasheet

10 % Off

USD

3,299

2,969

Single User License

10 % Off

USD

5,499

4,949

Five User License

15 % Off

USD

6,999

5,949

Corporate License

15 % Off

USD

8,199

6,969

Datasheet

One User

USD 3,299

USD 2,969

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 5,499

USD 4,949

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 6,999

USD 5,949

tax inclusive*

  • All Selected Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 8,199

USD 6,969

tax inclusive*

  • All Selected Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124